

Dissertação / Artigo de Revisão Bibliográfica  
Mestrado Integrado em Medicina

## **Treatment of HIV-associated Psoriasis**

---

Nuno Brochado Pinto da Silva Queirós

**Orientador:**

**Prof. Doutor Tiago Torres**

Porto, Maio de 2017

## **TREATMENT OF HIV-ASSOCIATED PSORIASIS**

(ARTIGO SUBMETIDO PARA PUBLICAÇÃO NA REVISTA ACTAS DERMO-SIFILOGRÁFICAS)

Nuno Brochado Pinto da Silva Queirós

nuno020@gmail.com

Artigo de Revisão Bibliográfica, Mestrado  
Integrado em Medicina submetido no Instituto  
de Ciências Biomédicas Abel Salazar

Ano letivo 2016/2017

Orientador: Prof. Doutor Tiago Torres

Grau académico: Licenciado em Medicina e  
Doutorado em Ciências Médicas

Título profissional: Especialista em  
Dermatologia e Venereologia; Assistente  
Hospitalar no Centro Hospitalar e  
Universitário do Porto

Afiliação: Instituto de Ciências Biomédicas  
Abel Salazar, Rua de Jorge Viterbo, n.228,  
4050-313 Porto

## **Agradecimentos**

Gostaria de agradecer ao meu orientador, Prof. Doutor Tiago Torres, pelas orientações, sugestões, dedicação e disponibilidade sempre demonstrada para me ajudar.

Muito obrigado.

## **Resumo**

Introdução – A prevalência de doentes HIV está a aumentar em todo o mundo, uma vez que a sua esperança média de vida aumentou com a introdução dos agentes antirretrovirais. Estes doentes desenvolvem muitas vezes doenças inflamatórias que são frequentemente refratárias ao tratamento.

A Psoríase é uma doença inflamatória sistémica, associada tanto a sofrimento físico como psicológico, e pode ser a primeira manifestação da infeção por HIV.

Em doentes HIV, esta doença tem tendência a ser mais grave, ter apresentações atípicas e os tratamentos prescritos têm menores taxas de eficácia. Embora a Psoríase leve a moderada seja tratável, a doença grave é de tratamento mais difícil, e os efeitos secundários dos fármacos imunossuppressores, como as infeções oportunistas, são a maior preocupação.

Objetivos – Proponho-me a realizar uma pesquisa de artigos científicos em bases de dados disponíveis (Pubmed, Medscape, revistas científicas, entre outras,) e estruturar a informação selecionada numa dissertação concisa sobre o tema.

Desenvolvimento – Psoríase foi observada em todos os estádios da infeção por HIV, incluindo como uma manifestação da síndrome inflamatória de reconstituição imune. Muitos dos tratamentos sistémicos da psoríase são imunossuppressores e podem ter complicações severas em contexto HIV.

Terapêuticas tópicas são utilizadas para a doença leve ou moderada, ou na moderada a grave como adjuvante. Deste modo, podem ser usadas isoladamente ou associadas com fototerapia/agentes sistémicos.

Nos doentes HIV, os antirretrovirais devem ser considerados como terapia de primeira linha para psoríase moderada a grave, e em alguns doentes podem ser utilizados em monoterapia.

Agentes sistémicos orais são utilizados como segunda linha. Os retinóides orais são comumente utilizados para este efeito e representam uma alternativa não imunossupressora.

Em doentes refratários ao tratamento, o uso de imunossuppressores como o Metotrexato, Ciclosporina e Hidroxiureia são uma opção, embora o risco de surgimento de infeções oportunistas seja uma preocupação.

Por outro lado, os inibidores do TNF- $\alpha$  são geralmente utilizados juntamente com fototerapia ou quando as terapias sistêmicas convencionais falham, são contraindicadas ou não toleradas.

Conclusões – O tratamento da Psoríase em doentes HIV é um desafio, e deve ser baseado na gravidade da doença, e no risco-benefício de cada tratamento. Os tratamentos de primeira linha incluem terapia tópica, fototerapia, antirretrovirais, e em segunda linha retinoides orais. Na doença refratária tratamento cuidadoso com imunossupressores deve ser considerado. Agentes biológicos podem também ser uma boa opção para estes casos. No entanto, independentemente da terapia utilizada, estes doentes devem ser seguidos atentamente, devido ao potencial risco de efeitos adversos, com monitorização regular das contagens CD4 e viremia.

## Índice

Abstract .....	1
Introduction.....	2
Psoriasis .....	2
HIV .....	4
Psoriasis and HIV .....	6
Clinical Features.....	8
Diagnosis and differential diagnosis .....	9
Treatment.....	11
Conclusions.....	15
References .....	15

## **Abstract**

HIV prevalence is increasing worldwide as people on antiretroviral therapy are living longer. These patients are often susceptible to debilitating inflammatory disorders that are frequently refractory to standard treatment. Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection. In this population, psoriasis tends to be more severe, to have atypical presentations and higher failure rates with the usual prescribed treatments.

Management of moderate and severe HIV-associated psoriasis is challenging. Systemic conventional and biologic agents may be considered, but patients should be carefully followed up for potential adverse events, like opportunist infections, and regular monitoring of CD4 counts and HIV viral loads.

**Keywords:** biologic agents; HIV; phototherapy; psoriasis; topical therapy

## **Introduction**

HIV prevalence is increasing worldwide as patients on antiretroviral therapy (ART) are living longer. In 2012 an estimated 35.3 million people were living with HIV.<sup>1</sup>

Dermatological disorders, such as psoriasis, can be the presenting feature of HIV infection. Moreover, in the HIV-infected population, psoriasis tends to be more severe (with severe disease correlating with higher immunosuppression)<sup>2,3</sup>, to have atypical presentations and higher failure rates with the usual prescribed treatments.<sup>4</sup> Although mild psoriasis is usually manageable, moderate to severe disease is more difficult to treat, and side effects from immunosuppressive drugs, such as, opportunistic infections, are the main concern.

This review discusses the pathogenesis, clinical features and management of HIV-associated psoriasis.

## **Psoriasis**

Psoriasis is a systemic inflammatory disorder<sup>5</sup>, associated with both physical and psychological burden.<sup>6</sup>

Five types of psoriasis have been described: plaque-type psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis (either localized or generalized pustular psoriasis), and erythrodermic psoriasis.<sup>5</sup> Concomitant psoriatic arthritis occurs in up to 30-40% of patients.<sup>7</sup> Psoriasis shows characteristic histopathological changes including epidermal acanthosis, hyperkeratosis, and parakeratosis, as well as premature desquamation of the stratum corneum. In the dermis, dilated and contorted blood vessels reach into the tips of the dermal papillae. There is also an inflammatory infiltrate



containing T cells, and an increased number of macrophages, mast cells and neutrophils. These cells accumulate within the epidermis forming Munro's microabscesses.<sup>5</sup>

Involvement of the immune system in psoriasis is widely accepted.<sup>8,9</sup> Specific subpopulations of dendritic cells (DCs), both myeloid (mDCs) and plasmacytoid (pDCs) could be recognized as central in the early pathogenetic steps of psoriasis.<sup>10</sup> Indeed, their activation induced by chemerin, LL37-DNA or LL37-RNA complexes, could trigger the psoriasis inflammatory cascade through the production of several proinflammatory mediators.<sup>11–13</sup> pDCs mainly contribute producing IFN- $\alpha$ , while mDCs secrete IL-20, which promotes keratinocyte proliferation, nitric oxide, TNF- $\alpha$ , IL-12 (Th1-differentiating cytokine) and IL-23, which sustains differentiation, activation and expansion of IL-17-producing CD4+ T cells.<sup>14–16</sup> Additionally, IL-23 stimulates other IL-17-producing T cells including CD8+ T cells, named T cytotoxic (Tc)-17,  $\alpha/\beta$  and  $\gamma/\delta$  T cells.<sup>17–21</sup> Furthermore, various immune cells, namely neutrophils, mast cells and innate lymphoid cells, contribute to the elevated IL-17 expression levels detected in lesioned psoriatic skin.<sup>22–25</sup> Although less pathogenically relevant compared with the IL-23/Th17 pathway, increasing evidence also suggested an involvement of multiple T-cell subsets (i.e., Th1, Th9, Th21 and Th22, Tc1) in psoriasis pathogenesis.<sup>17,26,27</sup> Tissue cells, especially keratinocytes, but also fibroblasts and endothelial cells are the key responding cells to these inflammatory pathways. T-cell cytokines stimulate proliferation and activation of keratinocytes, inducing acanthosis and, in turn, production of several proinflammatory mediators including IL-1 $\beta$ , IL-6, TNF- $\alpha$ , chemokines and anti-microbial peptides, which sustain and amplify immune cell recruitment, retain and activation within lesional skin.<sup>17,28</sup>

Psoriasis is also associated with several important comorbidities, including Crohn's disease, cancer, depression, non-alcoholic fatty liver disease, metabolic syndrome (or its components), and cardiovascular disease (CVD).<sup>29,30</sup> These associations might be due to similarities in the genetic basis and due to systemic inflammation mainly seen in severe psoriasis.<sup>31</sup>

## **HIV**

There are two types of HIV: HIV-1 and HIV-2. HIV-1 has marked genetic diversity as a consequence of the error-prone function of reverse transcriptase, resulting in a high mutation rate. HIV-2 is largely confined to West Africa, less transmissible and although it causes a similar illness, immunodeficiency progresses more slowly.<sup>32</sup>

The hallmark of HIV infection is the progressive depletion of CD4 T cells due to reduced production and increased destruction. CD4 T cells are eliminated by direct infection, and bystander effects of syncytia formation, immune activation, proliferation, and senescence. In early infection, a reduction in circulating CD4 T cells is followed by recovery to near normal concentrations, which slowly decreases by about 50-100 cells/ $\mu$ L per year.<sup>33</sup> HIV infection is also characterized by a marked increase in immune activation, which includes both the adaptive and innate immune systems.<sup>34</sup> The drivers for immune activation include the direct effects of HIV as a ligand for the Toll-like receptor (TLR7 and TLR 8) expressed on plasmacytoid dendritic cells, leading to production of interferon- $\alpha$ ;<sup>35</sup> microbial translocation, with lipopolysaccharide as a potent activator of TLR4 leading to the production of proinflammatory cytokines such as IL-6 and TNF- $\alpha$ ; <sup>36</sup> co-infection with viruses that induce profound expansion of activated T cells; <sup>37</sup> and a reduced ratio of T-helper-17 and regulatory T cells, especially

in the gastrointestinal tract.<sup>38</sup> Evidence of residual inflammation or increased immune activation exists, even in patients with HIV with adequate CD4 T cell restoration on ART.

Aging with HIV is often linked to non-infectious comorbidities, including CVD, hypertension, type 2 diabetes mellitus, chronic kidney disease, osteopenia/osteoporosis, and non-AIDS cancers. These heterogeneous comorbidities share age and presumably HIV-infection as independent risk factors, and tend to aggregate into complex multi-morbidity patterns.<sup>39,40</sup> The pathophysiology of HIV-associated CVD includes an intricate interplay of inflammation, direct effects of HIV proteins, immune dysfunction, drug effects, malnutrition, and other factors. Inflammation and dyslipidemia drive the pathophysiology of coronary artery disease (CAD) in patients infected with HIV. In particular, persistent HIV viral replication,<sup>41</sup> microbial translocation,<sup>42</sup> and coinfections (eg, cytomegalovirus) contribute to a proinflammatory milieu that accelerates atherosclerosis.<sup>43</sup> The development of ART transformed HIV from an illness with a fatal outcome to a chronic manageable disease. Standard regimens combine two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor. After initiation of ART, the plasma viral load decreases to concentrations below the lower limit of detection of available commercial assays in most people within 3 months. By contrast, the recovery of CD4 T cells in treated individuals is variable.<sup>44</sup> However, prolonged ART use predisposes to dyslipidemia, hyperglycemia, and lipodystrophy, among other side effects.<sup>45</sup> Protease inhibitors (PIs), particularly older generation PIs, are commonly implicated in ART-associated dyslipidemia, and are associated with greater risk of acute myocardial infarction.<sup>46,47</sup> They are postulated to increase CVD risk by inducing dyslipidemia and reactive oxygen species production, with resultant

mitochondrial dysfunction, fatty infiltration in liver and muscle, and insulin resistance.

<sup>48</sup> In high income countries, these effects, compounded with the cardiac effects of aging and inflammation, contribute to an increased risk of numerous CVDs. <sup>45</sup> On the other hand, in regions where ART initiation is often delayed and access is limited, the predominant manifestations are still related to opportunistic, infection-related myopericardial disease. <sup>49</sup>

### **Psoriasis and HIV**

Psoriasis has been observed in all stages of HIV infection and in some patients may be the initial presentation of the infection. In patients with pre-existing psoriasis, exacerbation of the disease is common when HIV infection occurs. <sup>50</sup>

Exacerbations of psoriasis by staphylococcal and streptococcal infection are also more common in patients with HIV than in those without, and heavy colonization prolongs the disease course. <sup>51</sup> Interestingly, it has been shown that genetic variants that contribute to anti-viral immunity may predispose to the development of psoriasis, as psoriasis patients are significantly more likely to have gene variants protective against HIV-1 disease. It was also found that the compound genotype KIR3DS1 plus HLA-B Bw4-80I, which respectively encode a natural killer cell activating receptor and its putative ligand, significantly increase psoriasis susceptibility and is associated with delay of progression to AIDS. <sup>52</sup>

In HIV context, T-cell imbalance, may be responsible in part for the development of worsening of psoriasis, due to the depletion of CD4 suppressor T cells, resulting in unchecked proinflammatory pathways. <sup>53</sup> Furthermore, HIV RNA transcripts have been identified in the skin of patients with HIV-associated psoriasis and within CD4 Factor

XIIIa+ dermal dendritic cells, which suggests a direct role of HIV and is compatible with worsening disease with the higher viral loads associated with progressive immunodeficiency.<sup>54</sup> HIV might also directly trigger psoriasis as a costimulatory factor through antigenic presentation or as a source of superantigens.<sup>53</sup> In HIV-associated psoriasis HIV Negative Regulatory Factor (nef) protein has superantigen properties.<sup>55</sup> Moreover, infections by virus and bacteria, which are common in HIV, might contribute to epitope spreading.<sup>54</sup>

Psoriasis has also been reported as a manifestation of HIV-related immune reconstitution inflammatory syndrome (IRIS). IRIS is an exacerbation or emergence of a previously unknown disease resulting from rapid restoration of pathogen-specific immune responses to pre-existing antigens combined with immune dysregulation, which happens shortly after initiation of ART. IRIS happens more commonly when ART is started in patients with low CD4 counts or soon after starting treatment for opportunistic infections. Strategies to reduce IRIS include initiation of ART at high CD4 counts, delayed initiation in patients with an infection, and screening for and prevention of opportunistic infections.<sup>56</sup> There is emerging evidence that one of the immunopathogenic mechanisms of IRIS involves the rapid and dysregulated shift from the T helper 2 predominant state of advanced HIV infection to the Th1 and Th17 dominant state of immune recovery.<sup>57</sup>

As discussed above, HIV-infection and psoriasis are conditions in which CVD are an important group of comorbid diseases. As such, screening, monitoring and treatment of cardiometabolic risk factors and CVD is important in psoriasis patients infected with HIV, since these patients are more prone to develop such diseases.

## **Clinical Features**

Incidence rates of Psoriasis in HIV patients are similar to those reported in the general population.<sup>4</sup> However, misleading and unusual clinical presentations, severe disease, and frequent exacerbations are characteristic.<sup>51</sup> Although all clinical subtypes of psoriasis may occur in patients with HIV-associated psoriasis, guttate, inverse, and erythrodermic occur with higher frequencies.<sup>2,3,58</sup> Often, more than one morphological type of psoriasis may coexist in a single patient, which is a distinguishing hallmark feature of HIV-associated psoriasis.<sup>3</sup>

As in non-HIV patients, plaque-type psoriasis is the most common form of the disease, and accounts for about 90% of cases. However, in this specific population there is a predilection for scalp lesions, palmoplantar and flexural involvement, as well as a trend towards severe immunodeficiency with CD4 counts below 200 cells/mm<sup>3</sup>.<sup>4,59</sup> On the other hand, different clinical variants can develop over the course of the disease. Often there is no family history of psoriasis.<sup>54</sup>

Sebopsoriasis is more common in patients with HIV. The clinical features represent an overlap between seborrheic dermatitis and psoriasis. Greasy scales with exudative crusts affect seborrheic areas on the scalp, retroauricular, perinasal, and flexural areas, and upper trunk.<sup>60</sup> Sebopsoriasis can be triggered by yeasts, and the effectiveness of systemic or topical antifungals is helpful in distinguishing this variant from classic psoriasis.<sup>61</sup>

Rupioid psoriasis is one of the rarer variants of psoriasis, and has also been reported as a manifestation of HIV-associated psoriasis. This variant is characterized by limpet-like, cone-shaped, hyperkeratotic nodules and plaques covered with an exudative crust typically presenting on the limbs.<sup>54</sup>

Psoriatic arthritis is much more destructive and refractory to conventional treatments in the HIV population, and its prevalence is also greatly increased compared with its immunocompetent counterpart.<sup>62,63</sup> Reactive arthritis prevalence is also higher in patients with HIV. This disease is a seronegative spondyloarthropathy characterized by a triad of arthritis, urethritis, and conjunctivitis.<sup>64</sup> A reactive arthritis-like psoriasis syndrome is a recognized presentation in HIV-associated psoriasis.<sup>51</sup> The typical cutaneous presentation of this variant, seen in more than half of patients, is keratoderma blennorrhagica with palmoplantar psoriasiform plaques. The histology is identical to that of pustular psoriasis.<sup>54</sup>

### **Diagnosis and differential diagnosis**

Cutaneous diseases are common manifestations of HIV infection and AIDS, and may be indicative of the degree of immune dysfunction. Psoriasis can be the presenting feature of HIV infection and can provide a clinical clue as to the state of the patient's immune system.<sup>65</sup> The patient's history should include details of family members with the disease, and potential trigger factors, such as present infections or new medications.<sup>66</sup> As in non-HIV patients, psoriasis diagnosis is usually made on clinical findings and skin biopsy is rarely needed. The Psoriasis Area and Severity Index (PASI) score is usually used to quantify disease severity.<sup>67</sup> Joint involvement should also be inquired, especially in HIV patients. In the presence of the extremely rare rupoid psoriasis, physicians should suspect immunosuppression, such as HIV/AIDS, or other immune dysregulation.<sup>65</sup>

The most common differential diagnosis of psoriasis includes tinea infection, seborrheic dermatitis and eczema of several causes. less common differential diagnosis

includes lichen planus, pityriasis rubra pilaris (PRP), pityriasis rosea and cutaneous lymphoma.<sup>59</sup> While PRP is a rare disease that can be associated with HIV infection (type VI) and is characterized by follicular keratotic papules or plaques that may coalesce to form erythematous or salmon-colored plaques that can develop scales<sup>68</sup>, cutaneous non-Hodgkin's lymphomas are rare in patients with HIV-1 infection and almost all of the cases reported are of T-cell lineage with histopathological features of mycosis fungoides or Sezary syndrome.<sup>69</sup>

Papulosquamous secondary syphilis might clinically and histologically resemble psoriasis and can be distinguished by other clinical clues of syphilis, such as so-called moth-eaten alopecia, condylomata lata in the flexures and perineum, and positive syphilis serology. A high index of suspicion is needed since false negative syphilis serology might initially be encountered due to the so-called prozone phenomenon associated with high treponemal loads with HIV.<sup>54</sup>

Annular psoriasis might be confused with ringworm; skin scrapings for fungal microscopy and culture help distinguish the latter. Microscopy can also be helpful to exclude crusted scabies, to which patients with HIV are prone, and is highly contagious if undiagnosed. The clinical presentation can mimic psoriasis since the lesions are often non-pruritic and present as scaly plaques on the skin, scalp and nails.<sup>70</sup>

In cases of nail psoriasis, care must be taken to exclude onychomycosis, since the clinical features can be similar and is common in HIV patients.<sup>54</sup>

Some patients with erythrodermic psoriasis have large scales resembling either lamellar ichthyosis or a chronic erythrodermic drug eruption. Patients infected with HIV are particularly prone to the latter; hence, a careful history and a high index of suspicion



are needed. These patients can develop generalized skin failure associated with higher mortality.<sup>54</sup>

### **Treatment**

The treatment of psoriasis in HIV-infected patients poses a distinct therapeutic challenge as HIV-associated psoriasis is a T-cell mediated disease in the setting of T-cell depletion. Many of the systemic treatments for psoriasis are immunosuppressive and potentially can lead to severe complications in the setting of HIV infection.<sup>3</sup>

Topical therapies may be used alone or in combination with other treatment modalities, including phototherapy and systemic agents. These therapies are appropriate for treatment of mild to moderate disease or as an adjunctive treatment for moderate to severe disease.<sup>71</sup>

Glucocorticosteroids, vitamin D derivatives, or combinations of both are usually sufficient to manage mild disease. Topical calcineurin inhibitors are used for difficult to treat sites, such as the intertriginous areas or the face.<sup>59</sup> Side effects from topical therapies in HIV patients are comparable with the non-HIV-infected population, and similar caution should be exercised when using these agents.<sup>71</sup>

Phototherapy (narrow-band UVB and PUVA) and/or systemic therapy is needed for patients with moderate to severe disease. Both UVB and PUVA have been used in the treatment of HIV-associated psoriasis. As in the non-HIV infected population, phototherapy is clinically effective and provides substantial relief in patients with debilitating disease.<sup>71</sup> The carcinogenic potential of PUVA limits its long term use.<sup>59</sup> A potential problem associated with the use of UV light is photosensitivity. Patients with HIV are prone to photosensitivity either directly due to HIV or ART.<sup>72</sup> Care must be taken when selecting patients since there is a raised incidence of non-melanoma skin cancer

and melanoma in patients receiving more than 250 treatments of PUVA <sup>73,74</sup>but overall UVB is thought to be safe. <sup>70</sup>

In HIV patients, ART should also be considered as a first-line therapy for moderate to severe psoriasis, and in some patients can be used as monotherapy. <sup>71</sup> Improvement of HIV associated psoriasis after the initiation of ART has been reported in several case reports. <sup>75,76,77</sup>

As second-line therapy for moderate to severe psoriasis, systemic oral agents are recommended. Oral retinoids are the most commonly used and represent an effective, non-immunosuppressive alternative. Retinoids are successful as monotherapy or as part of combination regimens, mainly with UV therapy. An additional effect is that lower cumulative doses of UV can be used. Dosing for HIV patients is similar to the non-HIV, although higher doses may be required to achieve optimal results. <sup>78,79</sup>

In refractory patients immunosuppressants such as methotrexate (MTX), cyclosporine (CSA) and hydroxyurea are an option; however, in the HIV-infected population opportunistic infections are a concern.

Although MTX is a key treatment in classic psoriasis and has been used for HIV-associated psoriasis, it is hepatotoxic and can cause leucopenia and opportunistic infections, hence it should be used with caution. <sup>54</sup>

Cyclosporine exerts its immunomodulatory effect by inhibiting the activation of CD4 T cells via calcineurin inhibition. In published cases of treatment of HIV-associated psoriasis with CSA, patients experienced rapid clearing of psoriasis without the development of opportunistic infections or worsening of immunosuppression. <sup>80,81</sup> On the other hand, careful monitoring for nephrotoxicity and hypertension is needed. Cyclosporine is recommended for short intermittent courses of up to 12 weeks. It can

also be used when rapid remission is needed in potentially lethal psoriasis variants such as erythroderma or generalized pustular psoriasis.<sup>54</sup>

Hydroxyurea is a systemic immunosuppressive drug. In addition to its anti-psoriatic effects, it has also been shown to have antiviral effects. This dual effect makes it a drug to consider when treating HIV-associated psoriasis. There are multiple reports that discuss the safety and efficacy of hydroxyurea in psoriasis and HIV separately. A 2011 review suggests that hydroxyurea is generally safe and effective. The main risk involves the hematologic adverse events (anemia, leukopenia, thrombocytopenia, and macrocytosis) which appear to be dose-dependent. Despite this fact, hydroxyurea may be considered as a viable option for patients with generalized psoriasis inadequately responsive to other safer options, whether the patient is HIV-positive or not.<sup>82</sup>

In the past decade, several biologic agents have been developed and approved for the treatment of psoriasis and psoriatic arthritis. TNF- $\alpha$  inhibitors include etanercept, adalimumab, and infliximab that are approved for the treatment of psoriasis and psoriatic arthritis, and golimumab that has been approved for psoriatic arthritis. Ustekinumab is a p40-IL12/23 inhibitor and is approved for both indications while secukinumab and ixekizumab are IL-17A inhibitors and have been approved for the treatment of psoriasis (secukinumab and ixekizumab) and psoriatic arthritis (secukinumab). Biologics agents are used for long-term treatment because there is no evidence of cumulative toxicity or drug–drug interactions. Furthermore, these agents have a good safety profile with only a small increase in opportunistic infections. TNF- $\alpha$  inhibitors are generally used after phototherapy and when conventional systemic therapies have either failed, were not tolerated, or were contraindicated. This second-

line use is in part due to the high direct costs for drugs, which are in the order of ten-times higher than for conventional systemic drugs.<sup>59</sup>

The American Academy of Dermatology reviewed 27 published cases of patients with HIV treated with TNF- $\alpha$  inhibitors. Although their review is limited because no randomized controlled trials have been performed with this population, it is proposed that reliable seropositive patients, who are adherent to medication regimens and frequent monitoring and have failed other treatment modalities, should be considered for treatment with TNF- $\alpha$  inhibitors, as anti-TNF- $\alpha$  agents have been used effectively in patients with HIV-associated psoriasis and HIV-associated psoriatic arthritis unresponsive to a combination methotrexate and ciclosporin.<sup>83, 84, 85</sup> TNF- $\alpha$  is a pivotal cytokine in the pathogenesis of granulomatous inflammation, stimulates HIV transcription in vitro<sup>86</sup> and is thought to be involved in the pathogenesis of aphthous ulcers, cachexia, dementia, fatigue and fever in HIV. A concern about the use of this therapy is the predisposition to other infections. If TNF- $\alpha$  inhibitors are to be used, other comorbidities that are often noted in HIV, such as tuberculosis, hepatitis B, and other opportunistic infections, need to be ruled out. Hepatitis C infection, however, is not seen as a contraindication to the use of TNF- $\alpha$  inhibitors because they have been used safely and effectively in patients with hepatitis C infection.<sup>87</sup> The same applies in non-HIV population.<sup>54</sup> Regarding ustekinumab there are reports of its use in refractory HIV-associated psoriasis, which has been described as safe and efficient, and without side effects or decrease in CD4 counts,<sup>88,89</sup> while the use and safety of secukinumab and ixekizumab have yet to be established in this population.

## **Conclusions**

The immunological dysfunction associated with HIV creates an environment that is favorable to developing psoriasis. The main postulated mechanisms are T cell imbalance and HIV being a source of superantigens, and a costimulatory factor through antigenic presentation.

Treatment of HIV-associated psoriasis can be challenging, and should be based on disease severity and the risks and benefits of each treatment should also be considered carefully. Recommended first line treatments include topical therapy, phototherapy, ART and secondarily oral retinoids. For refractory disease cautious treatment with systemic immunosuppressants should be considered. Biologic agents may prove to be a good option in these cases. Regardless of therapy HIV patients should be followed up carefully for potential adverse events, with regular monitoring of CD4 counts and HIV viral loads.

## **References**

1. Zaidi J, Grapsa E, Tanser F, Newell ML, Barnighausen T. Dramatic increases in HIV prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV surveillance study in rural kwazulu-natal. *AIDS* 2013; 27: 2301–05.
2. Mallon E, Bunker CB. HIV-associated psoriasis. *AIDS Patient Care & Stds* 2000;14:239-46
3. Montazeri A, Kanitakis J, Bazex J. Psoriasis and HIV infection. *Int J Dermatol* 1996;35:475-9.

4. Fernandes, S., Pinto, G. M., & Cardoso, J. (2011). Particular clinical presentations of psoriasis in HIV patients. *International Journal of STD & AIDS*, 22(11), 653–4. <https://doi.org/10.1258/ijsa.2011.010525>
5. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. *J Eur Acad Dermatol Venereol* 2012; 26 (suppl 2): 3–11
6. Dubertret L, Mrowietz U, Ranki A, et al, and the EUOPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUOPSO patient membership survey. *Br J Dermatol* 2006; 155: 729–36
7. Gladman DD, Brockbank J. Psoriatic arthritis. *Expert Opin Investig Drugs* 2000; 9: 1511–22
8. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. *Clin Rev Allergy Immunol* 2007; 33: 45–56.
9. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. *Exp Dermatol* 2007; 16: 779–98...
10. Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. *J Invest Dermatol* 2009;129:302-8
11. Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. *J Exp Med* 2009;206(1):249-58
12. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. *J Exp Med* 2009;206: 1983-94
13. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. *Sci Transl Med* 2011; 3:73ra19

14. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *J Exp Med* 2005; 202:135-43
15. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). *Proc Natl Acad Sci USA* 2005; 102:19057-62
16. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity* 2000; 13:715-25
17. Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. *Trends Immunol* 2013; 34:174-81
18. Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. *J Leukoc Biol* 2009; 86:435-43
19. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. *Immunity* 2011;35:596-610
20. Laggner U, Di Meglio P, Perera G, et al. Identification of a novel pro-inflammatory human skin-homing Vc9Vd2 T cell subset with a potential role in psoriasis. *J Immunol* 2011;187:2783-93
21. Ciric B, El-behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. *J Immunol* 2009;182: 5296-305
22. Ward NL, Umetsu DT. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. *J Invest Dermatol* 2014;134(9):2305-7

23. Teunissen M, Munneke M, Bernink J, et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR $\beta$  ILC3 in lesional skin and blood of psoriasis patients. *J Invest Dermatol* 2014;134:2351-60
24. Keijsers RRM, Hendriks AGM, van Erp PEJ, et al. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing ROR $\gamma$ t and IL-17. *J Invest Dermatol* 2014;134:1276-84
25. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. *J Immunol* 2011;187:490-500
26. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. *Nat Med* 2009;15(9):1013-15
27. Singh TP, Schön MP, Wallbrecht K, et al. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. *PLoS One* 2013;8:e51752
28. Lowes MA, Suárez-Farínas M, Krueger JG. Immunology of psoriasis. *Annu Rev Immunol* 2014;32:227-55
29. Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. *J Am Acad Dermatol* 2011; 65: 870–73.
30. Henseler T, Christophers E. Disease concomitance in psoriasis. *J Am Acad Dermatol* 1995; 32: 982–86.
31. Gupta Y, Moller S, Zillikens D, Boehncke WH, Ibrahim SM, Ludwig RJ. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. *Exp Dermatol* 2013; 22: 552–53.
32. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. *Cold Spring Harb Perspect Med* 2011; 1: 006841



33. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. *Nature* 2013; 498: 376–79
34. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. *Biomarkers Med* 2011; 5: 171–86
35. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. *Nat Med* 2009; 15: 955–59
36. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006; 12: 1365–71.
37. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. *AIDS* 2006; 20: 2275–83.
38. Prendergast A, Prado JG, Kang YH, et al. HIV-1 infection is characterized by profound depletion of CD161<sup>+</sup> Th17 cells and gradual decline in regulatory T cells. *AIDS* 2010; 24: 491–502.
39. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2011;53(11):1120–6. doi: 10.1093/cid/cir627 pmid:21998278.
40. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEHIV cohort study.

- Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;59(12):1787–97. doi: 10.1093/cid/ciu701 pmid:25182245.
41. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV positive adults on suppressive antiretroviral therapy. *AIDS* 2010;24(16):2451–60.
  42. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006; 12(12):1365–71
  43. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. *AIDS* 2006;20(18):2275–83.
  44. Maartens, G., Celum, C., & Lewin, S. R. (2014). HIV infection: Epidemiology, pathogenesis, treatment, and prevention. *The Lancet*, 384(9939), 258–271. [https://doi.org/10.1016/S0140-6736\(14\)60164-1](https://doi.org/10.1016/S0140-6736(14)60164-1)
  45. Bloomfield, G. S., & Leung, C. (2017). Cardiovascular Disease Associated with Human Immunodeficiency Virus Infection, 35, 59–70. <https://doi.org/10.1016/j.ccl.2016.09.003>
  46. Sabin CA, Worm SW, Weber R, et al, D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet* 2008;371(9622): 1417–26.
  47. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antirretroviral drugs and the risk of myocardial infarction. *N Engl J Med* 2007;356(17):1723–35.
  48. Anuurad E, Bremer A, Berglund L. HIV protease inhibitors and obesity. *Curr Opin Endocrinol Diabetes Obes* 2010;17(5):478–85.
  49. Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. *Nat Clin Pract Cardiovasc Med* 2009;6(2):120–7.

50. Leal L, Ribera M, Daudén E. [Psoriasis and HIV infection]. *Actas Dermosifiliogr*. 2008 Dec;99(10):753-63.
51. Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and reactive arthritis. *Arch Dermatol* 1987; 123: 1622–32.
52. Chen, H., Hayashi, G., Lai, O. Y., Dilthey, A., Kuebler, P. J., Wong, T. V., ... Liao, W. (2012). Psoriasis patients are enriched for genetic variants that protect against hiv-1 disease. *PLoS Genetics*, 8(2). <https://doi.org/10.1371/journal.pgen.1002514>
53. Fife DJ, Waller JM, Jeff es EW, Koo JY. Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. *Dermatol Online J* 2007; 13: 4
54. Morar, N., Willis-Owen, S. A., Maurer, T., & Bunker, C. B. (2010). HIV-associated psoriasis: pathogenesis, clinical features, and management. *The Lancet Infectious Diseases*, 10(7), 470–478. [https://doi.org/10.1016/S1473-3099\(10\)70101-8](https://doi.org/10.1016/S1473-3099(10)70101-8)
55. Torres BA, Johnson HM. Identification of an HIV-1 Nef peptide that binds to HLA class II antigens. *Biochem Biophys Res Commun* 1994; 200: 1059–65
56. Lawn SD, Meintjes G. Pathogenesis and prevention of imune reconstitution disease during antiretroviral therapy. *Expert Rev Anti Infect Ther* 2011; 9: 415–30
57. Tripathi, S. V., Leslie, K. S., Maurer, T. A., & Amerson, E. H. (2015). Psoriasis as a manifestation of HIV-related immune reconstitution inflammatory syndrome. *Journal of the American Academy of Dermatology*, 72(1), e35–e36. <https://doi.org/10.1016/j.jaad.2014.09.032>
58. Bartlett BL, Khambaty M, MendozaN, Tremaine AM, Gewirtzman A, Tyring SK. Dermatological management of human immunodeficiency virus. *Skin Therapy Lett* 2007;12:1-3

59. Boehncke, W.-H., & Schön, M. P. (2015). Psoriasis. *The Lancet*, 386(9997), 983–994.  
[https://doi.org/10.1016/S0140-6736\(14\)61909-7](https://doi.org/10.1016/S0140-6736(14)61909-7)
60. Pillai S, DiPaolo F. Bilateral panuveitis, sebopsoriasis, and secondary syphilis in a patient with acquired immunodeficiency syndrome. *Am J Ophthalmol* 1992; 114: 773–75
61. Doring HF. Treatment of sebopsoriasis—a clinical trial: an etiological approach. *Dermatologica* 1984; 169: 125–33
62. Dover JS, Johnson RA. Cutaneous manifestations of human immunodeficiency virus infection. Part II. *Arch Dermatol*. 1991;14:1549–1558. doi: 10.1001/archderm.127.10.1549
63. Cedeno-Laurent F, Gomez-Flores M, Mendez N, et al. New insights into HIV-1-primary skin disorders. *J Int AIDS Soc*. 2011;14:5
64. Keat A, Rowe I. Reactive arthritis and associated arthritides. *Rheum Dis Clin North Am* 1991; 17: 25–42
65. Mendoza, N., Yang, B., Patiblanda, K., & Nicole, M. (2015). Psoriasis and HIV: Rubioid psoriasis , an uncommon presentation, (Figure 1), 1–4.
66. Henes JC, Ziupa E, Eifelder M, et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. *Rheumatol Int* 2014; 34: 227–34.
67. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. *Dermatology* 2005; 210: 194–99.
68. Leal, L., & Ribera, M. (2008). Psoriasis e infección por el virus de la inmunodeficiencia humana, 753–763.
69. Reports, C. (1999). Cutaneous T-cell Lymphoma and Human Immunodeficiency Virus Infection : 2 Cases and a Review of the Literature, 153–155.

70. Schlesinger I, Oelrich DM, Tying SK. Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations. *South Med J* 1994; 87: 352–56.
71. Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* 2010; 62: 291–99.
72. Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. *J Am Acad Dermatol* 2006; 54: 581–88
73. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. *J Invest Dermatol* 1988; 91: 120–24.
74. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. *J Am Acad Dermatol* 2001; 44: 755–61.
75. Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. *Scand J Infect Dis* 2006;38:74-5.
76. Mamkin I, Mamkin A, Ramanan SV. HIV-associated psoriasis. *The Lancet Infectious Diseases* 2007;7:496.
77. Chiricozzi, A., Saraceno, R., Cannizzaro, M. V., Nisticò, S. P., Chimenti, S., & Giunta, A. (2013). Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (ritonavir, atazanavir, emtricitabine, tenofovir). *Dermatology*, 225(4), 333–337. <https://doi.org/10.1159/000345762>
78. Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. *Drug Saf* 2003;26:605-24.

79. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. *Arch Dermatol* 1997;133:711-5
80. Allen BR. Use of cyclosporin for psoriasis in HIV-positive patient. *Lancet* 1992;339:686.
81. Tourne L, Durez P, Van Vooren JP, Farber CM, Liesnard C, Heenen M, et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. *J Am Acad Dermatol* 1997;37:501-2.
82. Lin, G. G., & Scott, J. G. (2012). NIH Public Access, 100(2), 130–134. <https://doi.org/10.1016/j.pestbp.2011.02.012>. Investigations
83. Barco D, Puig L, Alomar A. [Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection]. *Actas Dermosifiliogr*. 2010 May;101 Suppl 1:77-81.
84. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. *J Rheumatol* 2007; 34: 1353–55.
85. Gallitano, S. M., McDermott, L., Brar, K., & Lowenstein, E. (2016). Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. *Journal of the American Academy of Dermatology*, 74(5), 974–980. <https://doi.org/10.1016/j.jaad.2015.11.043>
86. Butera ST, Roberts BD, Folks TM. Ligand passing by the p75 tumour necrosis factor receptor enhances HIV-1 activation. *Cytokine* 1996; 8: 745–50.
87. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. *Autoimmun Rev* 2008; 8: 104–06.

88. Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat. 2012 Dec;23(6):398-9. doi: 10.3109/09546634.2011.579085.
89. Saeki H, Ito T, Hayashi M, Fukuchi O, Umezawa Y, Nobeyama Y, Teruya K, Nakagawa H. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1653-5. doi: 10.1111/jdv.12531